J&J Intensifies Search For Drugs With A New Development Center In Mumbai
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - From forging alliances for drug discovery research in India, Johnson & Johnson has taken one step forward and established in what it called "the first of its kind" late-phase new chemical entity Analytical and Pharmaceutical Development Center at its North Mumbai facility
You may also be interested in...
J&J Worldwide Chairman Paul Stoffels On Precompetitive Alliances, Patent Pools And Tropical Drugs: An Interview With PharmAsia News
For Paul Stoffels, worldwide chairman, pharmaceuticals at Johnson & Johnson, innovation has been a long-time passion. Stoffels is regarded as a specialist in HIV therapies. In 1997, he left Janssen Research Foundation to become the CEO of Tibotec-Virco, which he transformed from a technology-based research company into an integrated R&D organization focused on the discovery and development of new drugs and diagnostics for HIV/AIDS and infectious diseases.
J&J Worldwide Chairman Paul Stoffels On Precompetitive Alliances, Patent Pools And Tropical Drugs: An Interview With PharmAsia News
For Paul Stoffels, worldwide chairman, pharmaceuticals at Johnson & Johnson, innovation has been a long-time passion. Stoffels is regarded as a specialist in HIV therapies. In 1997, he left Janssen Research Foundation to become the CEO of Tibotec-Virco, which he transformed from a technology-based research company into an integrated R&D organization focused on the discovery and development of new drugs and diagnostics for HIV/AIDS and infectious diseases.
MNCs Increasingly Investing In Diseases Affecting Developing Countries – IFPMA
HONG KONG - Underscoring what may be a subtle but ongoing change in focus for the industry, pharmaceutical companies appear to be increasingly focused on chronic diseases, child and maternal health and other issues of developing countries